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Abstract
Background: Undergoing diagnostic evaluation for cancer has been associated with a high prevalence of anxiety
and depression and affected health-related quality of life (HRQoL). The aims of this study were to assess HRQoL,
anxiety, and depression pre- and post-diagnosis in patients undergoing diagnostic evaluations for cancer due to
non-specific symptoms; to examine changes over time in relation to final diagnosis (cancer yes/no); and to assess
the predictive value of pre-diagnostic psychological, socio-demographic and clinical factors.
Methods: A prospective, multicenter survey study of patients suspected to have cancer based on non-specific
symptoms was performed. Participants completed the EORTC-QLQ-C30 quality of life scale, HADS, SOC-13 and
self-rated health before and after completing diagnostic evaluations. Intra- and inter-group differences between
patients diagnosed with cancer versus patients with non-cancer diagnoses were calculated. The impact of baseline
psychological, socio-demographic, and medical factors on HRQoL, anxiety and depression at follow-up was
explored by bootstrapped multivariate linear regression analyses and logistic regression analyses.
Results: A total of 838 patients participated in this study; 679 (81 %) completed the follow-up. Twenty-two percent
of the patients received a cancer diagnosis at the end of the follow-up. Patients presented initially with a high
burden of symptoms and affected role and emotional functioning and global health/QL, irrespective of diagnosis.
The prevalence of clinical anxiety prior to knowledge of the diagnosis was 32 % in patients with cancer and 35 %
in patients who received a non-cancer diagnosis. HRQoL and anxiety improved after diagnosis, and a larger
improvement was seen in patients who received a non-cancer diagnosis. There were no intra- or inter-group differences
in the depression scores. The strongest predictors of global QL, anxiety, and depression after a known diagnosis were
baseline scores, co-morbidity and poor self-rated health.
Conclusions: Patients undergoing diagnostic evaluations for cancer based on non-specific symptoms experience a high
prevalence of anxiety and affected quality of life prior to knowledge of the diagnosis. The predictive value of the
baseline scores is important when assessing the psychological impact of undergoing diagnostic evaluations for cancer.
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Background
Undergoing diagnostic evaluations for suspected cancer
can be experienced as frightening because of the threat
of being seriously ill and because of the possible invasive
investigations needed to confirm or refute malignant dis-
ease [1–5]. Previous studies investigating patient experi-
ences in the diagnostic phase of cancer have primarily
focused on patients diagnosed with cancer [3–7]. Few
studies have examined the diagnostic experience of pa-
tients with an unknown diagnosis or with a non-cancer
result. Although mostly limited to suspicions of breast
cancer, these studies suggest that patients confronted
with the possibility of a cancer diagnosis experience high
levels of anxiety during the diagnostic phase [8–10]. A
high level of anxiety can interfere with the ability to per-
form daily activities and receive necessary information
and health care [2, 11, 12], and several studies have
shown that health-related quality of life (HRQoL) might
be affected [6–10]. Affected HRQoL in the diagnostic
phase has been associated with increased anxiety and
depression after diagnosis in patients diagnosed with can-
cer [11, 12]. The psychological impact of the diagnostic
phase is additionally highlighted by studies of outcomes
of breast cancer screenings, where patients with a non-
cancer outcome might later experience psychological
consequences [13, 14].
Danish studies have shown that approximately 50 % of
all cancer patients initially present with vague symptoms
or symptoms that are not specifically associated with
cancer [13, 14]. A Cancer Patient Pathway (CPP) for
patients with serious Non-Specific Symptoms and Signs
of Cancer (NSSC-CPP) was therefore introduced in
2012 in Denmark. The objectives of this pathway are to
offer patients an optimal evaluation and diagnosis, to
minimize passive waiting time, and to improve quality
of life during the diagnostic phase [15, 16]. A clinical
coordinator is attached to the pathway to optimize
logistics, and the aim is to diagnose or refute cancer or
any serious illness within 22 days. According to the
guidelines, patients are at referral to be informed about
the suspicion of cancer [17].
The measurement of patient reported outcomes (PROs)
prior to diagnosis might be crucial to provide a clear point
of comparison for later measurements and could facilitate
a more reliable interpretation of the results [18]. More-
over, understanding how patients cope with a potential
cancer diagnosis is important in determining their HRQoL
[18]. However, measuring coping with a life strain might
be difficult. The concept of Sense of Coherence (SOC),
although under discussion, has a broad theoretical base
and a growing body of empirical evidence supporting its
utility as a determinant for successful coping [18–22].
The concept of SOC is defined as an individual’s glo-
bal view of life and as an inner resource for coping
with stressful life events. The concept does not refer
to a particular coping strategy [18]. SOC was origin-
ally believed to represent a staple dispositional orien-
tation [19]. However, this degree of stability has been
questioned by several studies [20–22], and it remains
to be clarified if a stressful life experience, such as a
cancer diagnosis, affects levels of SOC [22].
Patients referred to the NSSC-CPP are suspected of
having cancer due non-specific or vague symptoms.
Knowledge about how these patients experience the
diagnostic phase and how this experience might be influ-
enced by the final diagnosis can be used to enhance evi-
dence based care in the diagnostic phase of cancer.
Therefore, the aims of this study were as follows: 1) to
assess HRQoL, symptoms of anxiety and depression,
sense of coherence, and self-rated health as measures of
PROs pre- and post-diagnosis in patients undergoing
diagnostic evaluations for cancer; 2) to examine changes
in PROs over time and in relation to the final diagnosis
(cancer yes/no); and 3) to assess the predictive value of
baseline scores, sense of coherence, self-rated health,
socio-demographic factors, and co-morbidity on global
QL, anxiety and depression after diagnosis.
Methods
Participants
A prospective survey study was carried out between
October 1, 2013, and September 30, 2014, at four hospitals
in the Capital Region, Denmark. All consecutive patients
referred to the NSSC-CPP during the study period were
eligible to participate in this study. The exclusion criteria
were patients younger than 18 years of age, patients with
cognitive disorders, and patients with language barriers
or if referral to the NSSC-CPP was due to metastasis
with unknown primary tumor. All participating patients
were asked to complete the European Organisation for
Research and Treatment of Cancer quality of life ques-
tionnaire (EORTC-QLQ-C30), the Hospital Anxiety
and Depression Scales (HADS), the Sense of Coherence
13-scale (SOC-13) and Self-Rated Health (SRH) prior to
diagnosis (baseline) and 30 days after referral (follow-up),
a point in time when clinical evaluations should have been
completed. The patients were aware of the suspicion of
cancer prior to the baseline assessment. The follow-up
questionnaire was sent with a stamped envelope. Patients
who did not return the questionnaire were sent a re-
minder after 2 weeks.
Questionnaires
HRQoL was assessed using the Danish version of the
EORTC-QLQ-C30 questionnaire (version 3.0) [23]. The
EORTC QLQ-C30 is a self-administered questionnaire
that was developed to cover the multi-dimensional con-
cept of HRQoL in cancer patients. The questionnaire
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consists of 30 items, which aggregate into one global
health/QL scale, five functional scales (physical, emo-
tional, role, cognitive and social functioning), three
symptom scales (fatigue, pain and nausea/vomiting), and
six single items assessing financial impact and various
symptoms. Each item is answered on a four-point scale,
from 1 (not at all) to 4 (very much), except for the global
health/QL items. These items have seven response op-
tions ranging from 1 (very poor) to 7 (excellent) [23, 24].
The raw score of each scale/single item is linearly
transformed according to the manual on a 0–100
scale [24]. A high score for the global health/QL scale
and functioning scales represents a high level of quality of
life and functioning. A high score for a symptom scale
represents a high level of symptomatology. Missing
items were imputed by the methods advocated by the
EORTC QLQ research group [24]. Differences in
mean scores of ten or more are regarded as clinically
significant [25].
Anxiety and depression were assessed using the Da-
nish version of the HADS. The HADS was developed to
measure symptoms of anxiety and depression in somat-
ically ill patients [26]. The scale is divided into an anx-
iety subscale (HADS-A) and a depression subscale
(HADS-D), both containing seven intermingled items.
The patients are asked to evaluate how they felt during
the last week. Each item is scored between 0 and 3,
where 0 is asymptomatic and 3 is considerable. The total
score for each of the two subscales is between 0 (no sign
of illness) and 21 (severe degree of anxiety or depres-
sion) [26, 27]. The HADS has been extensively used in
the field of cancer [28], and several studies have shown
good sensitivity and specificity with a cut-off score of 8+
for each of the two subscales [26, 29].
Sense of coherence was assessed using the 13-item
version of Antonovsky’s SOC Scale (SOC-13). The SOC-
13 contains three components: meaningfulness, compre-
hensibility, and manageability. All items are scored on a
7-point semantic differential scale. A total score is calcu-
lated, ranging from 13 to 91. A higher score indicates a bet-
ter SOC [19]. The validity and reliability of this scale have
been supported in numerous studies [30, 31], including
cancer populations [32, 33].
The SRH was measured by two single items asking the
participants to rate their overall current health and their
current health compared to three months ago. Both
items could be answered on a five point Likert scale ran-
ging from excellent (5) to really poor (1). These single
items have been shown to be a good predictor of morbid-
ity and mortality regardless of the precise wording of the
question [34–36].
At baseline and follow-up, participants were asked
whether they completed the questionnaire before or after
receiving knowledge of their diagnosis.
Demographics and medical information
The demographic variables were collected at baseline and
included self-reported age, gender, marital status, education
and employment status. Information on clinical variables
(symptoms at referral, duration of symptoms, exposures
and smoking) was obtained from the patients’ medical re-
cords. Information on the diagnoses and co-morbidities, in-
cluding previous cancer, was collected from the Danish
National Patient Registry [37]. Co-morbidities were scored
according to the Charlson’s Comorbidity Index [38].
Ethics
All participants provided informed consent before data
collection commenced. Approval from the National
Committee on Health Research Ethics was not required
(H-3-2013-061). The study was approved by The Danish
Data Protection Agency (HIH-2013-034). The baseline
characteristics for non-participants were obtained an-
onymously for dropout analyses.
Statistical analysis
Categorical variables are described as counts (%), and
continuous variables are described as means (SD) or me-
dians with the 25 to 75th interquartile ranges (IQR). Dif-
ferences in baseline characteristics were summarized
and compared between patients diagnosed with cancer
and patients who were not diagnosed with cancer using
the Pearson’s χ2-test, Student’s unpaired T-test or the
Wilcoxon rank sum test, as appropriate. The intra-group
difference of the EORTC-QLQ-C30, HADS, SOC and
SRH scores between baseline and follow-up within the
diagnosis groups (cancer yes/no) were calculated using
the Wilcoxon signed-rank test for continuous data and
McNemar’s χ2-test for categorical data. The inter-group
differences between the baseline and follow-up scores in
the two diagnosis groups were calculated using the Pear-
son’s χ2-test for categorical data and the Wilcoxon rank
sum test for continuous data, and the intra-group differ-
ences within the groups were estimated by the Wilcoxon
rank sum test. The differences between the groups were
also estimated by effect size and interpreted by Cohen’s cri-
teria: <0.20 none, 0.20–0.49 small, 0.50–0.79 moderate and
≥0.80 large [39]. The analysis was restricted to subjects for
whom both baseline and follow-up data were available.
The predictive value of the baseline values, socio-
demographic factors, and co-morbidity on global QL
was explored by bootstrapped multivariate linear regres-
sion with 2,000 repetitions. Logistic regression was used
to estimate the predictive value of the included variables on
clinical anxiety and depression (HADS score of ≥8). The
baseline score, age, gender, cancer diagnosis (yes/no), dur-
ation of symptoms (weeks), previous cancer in patient, co-
morbidities (0, 1, ≥2), marital status, education, occupation,
time when the questionnaire was completed at follow-up
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(before or after diagnosis), and hospital site were included
in all models in one single step. All tests were two-sided,
with a significance level at p <0.05. The analyses were car-
ried out using STATA 13.
Results
Patient characteristics
A flowchart providing an overview of the participating
patients is presented in Fig. 1. In total, 2,574 patients
were referred to the NSSC-CPP at one of the participat-
ing hospitals during the study period; 403 (16 %) pa-
tients were initially excluded, and 1,044 (48 %) patients
did not want to participate (‘Not enrolled’). Of the 1127
patients who provided informed consent, 289 (13 %)
never completed the questionnaire (‘Consent only’),
while 838 (39 %) returned a completed questionnaire
and were enrolled in the study (‘Enrolled’). A total of
679 (81 %) participants completed the follow-up.
There was no difference in the presence of a cancer
diagnosis between the participants who completed the
follow-up and those who did not complete the follow-up
(p=0.4). Enrolled patients were more likely to be diag-
nosed with cancer than ‘consent only’ patients. Diagnosis
was not available for the ‘not enrolled’ patients (Table 1).
The baseline characteristics are presented in Table 2 for
all enrolled patients and according to cancer diagnosis.
Quality of life over time and in relation to the final diagnosis
The difference in the EORTC-QLQ-C30 scores over time
in patients diagnosed and not diagnosed with cancer,
in addition to the difference between the two diagnosis
groups, are presented in Table 3.
Patients diagnosed with cancer experienced overall less
functioning and less or similar burden of symptoms at
follow-up compared to baseline. The difference was sta-
tistically significant for cognitive function and financial
difficulties. There was no significant difference in global
QL between the two time points. Patients not diagnosed
with cancer improved on all domains, except for cognitive
and social functioning where there was no difference be-
tween the two time points. There was no difference be-
tween the groups at baseline, except for in cognitive
function where patients diagnosed with cancer had a sig-
nificantly higher score at baseline. Patients diagnosed with
cancer had less role functioning at follow-up compared to
patients with a non-cancer diagnosis; a finding that was
both clinically and statistically significant. Patients diag-
nosed with cancer also experienced more dyspnea and ap-
petite loss at follow-up compared to patients with a non-
cancer diagnosis, and had a significantly larger decrease in
emotional, cognitive and social functioning over time.
Moreover, the change in the fatigue score between the two
time points was significantly less than in patients not diag-
nosed with cancer. Overall, the effect sizes were small.
Anxiety, depression, SOC and self-rated health over time
and in relation to final diagnosis
The difference in the HADS anxiety and depression,
SOC, and SRH scores over time and in relation to the
final diagnosis are presented in Table 4.
Fig. 1 Flowchart of patient enrolment
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There were no significant differences in the mean anxiety
score between the groups at baseline or follow-up. Using the
recommended cutoff score of eight points or more [26],
32 % of patients who were later diagnosed with cancer and
35 % of patients with a non-cancer diagnosis experienced
clinical anxiety prior to knowledge of their diagnosis. The
patients who were not diagnosed with cancer experienced a
significantly larger decrease at follow-up than the patients
with a non-cancer diagnosis.
The mean depression scores were lower than the anx-
iety mean scores, and 23 % of patients later diagnosed
with cancer and 25 % of patients with a non-cancer
diagnosis achieved a level of probable clinical depression
at baseline. There were no significant differences between
the groups at baseline or at follow-up, and there were no
significant intra-group differences between the diagnosis
groups. There were also no intra-group differences in the
SOC-13 scores between baseline and follow-up. The pa-
tients diagnosed with cancer had a significantly higher
SOC at baseline and at follow-up.
Forty-three percent of patients in both diagnosis groups
rated their current health as poor or very poor at baseline,
and both groups experienced an improvement after receiving
knowledge of their diagnosis. There were no significant dif-
ferences within or between the groups. At baseline, 57 % of
patients diagnosed with cancer rated their health as poor or
very poor compared to 3 months ago. Using the fair category
as a reference, there was a significant improvement in SRH
at follow-up compared to 3 months ago. A high proportion
of patients who were not diagnosed with cancer also rated
their health compared to 3 months ago as fair (48 %) or
(very) poor (44 %) at baseline. There was a significant im-
provement at follow-up. There was a significant difference
between the diagnosis groups at baseline and follow-up, and
patients not diagnosed with cancer experienced a signifi-
cantly larger increase in SRH compared to 3 months ago
than patients with a non-cancer diagnosis.
Predictors of quality of life, anxiety, and depression after
a known diagnosis
The results from the regression analysis of predictors of
global QL are presented in Table 5.
The strongest predictors of global QL after a known
diagnosis were the baseline global QL score, baseline de-
pression score, (very) poor current SRH at baseline, age,
co-morbidity and unemployment. None of the included
Table 1 Comparison between Enrolled, Consent only and Not Enrolled patients
Enrolled Consent only Not enrolled p-value
838 289 1044
Age, mean (SD), years 63.6 (13.5) 60.5 (17.1) 64.7 (16.4) <0.001a
Gender, n (%), women 443 (53) 162 (56) 591 (57) 0.25
Symptoms at referral, n (%)
Weight loss 297 (35) 111 (38) 346 (33) 0.23
Pain 122 (15) 57 (20) 161 (15) 0.11
Suspicion of major illness/cancer 127 (15) 5 (2) 30 (3) <0.001c
Abnormal blood tests 106 (13) 36 (12) 118 (11) 0.63
Fatigue 105 (13) 40 (14) 151 (14) 0.48
Pathological lymph node 72 (9) 24 (8) 71 (7) 0.31
Anemia 71 (8) 28 (10) 74 (7) 0.28
Feeling ill 41 (5) 16 (6) 34 (3) 0.09
Night sweats 46 (5) 20 (7) 43 (4) 0.12
Loss of appetite/nausea 35 (4) 25 (9) 45 (4) 0.01a
Fever 34 (4) 10 (3) 34 (3) 0.65
Abdominal disorder 31 (4) 18 (6) 43 (4) 0.18
Increased contact to health system 2 (0.2) 1 (0.3) 0 0.48
Recurrent deep venous thrombosis 1 (0.1) 1 (0.3) 0 0.62
Increased use of medication 0 0 0
Other 177 (21) 72 (25) 90 (9) <0.001b
Cancer diagnosis, n (%) 188 (22) 35 (12) <0.001a
aSignificant difference between enrolled and consent only
bSignificant difference between enrolled and not enrolled
cSignificant difference between enrolled and consent only, and significant difference between enrolled and not enrolled
Significant results are higligthed in bold
Moseholm et al. Health and Quality of Life Outcomes  (2016) 14:80 Page 5 of 12
variables reached a score difference of ten, and therefore,
none of the variables had a clinically significant impact.
The results of the regression analyses of anxiety and de-
pression after a known diagnosis are presented in Table 6.
Anxiety at baseline was found to be the most significant
predictor of clinical anxiety after a known diagnosis, along
with the degree of SOC at baseline, the baseline glo-
bal QL score, and follow-up completed post-diagnosis.
Table 2 Baseline characteristics
Cancer
All patients n=838 yes n=188 no n=650 p-value
Age, mean (SD), years 63.6 (13.5) 68.9 (10.5) 62.0 (13.8) <0.001
Gender, n (%), men 395 (47) 107 (57) 288 (44) 0.002
Co-morbidity, n (%)
0 393 (47) 12 (6) 381 (58)
1 258 (31) 111 (59) 147 (23)
≥2 187 (22) 65 (35) 122 (19) <0.001
Duration of symptoms, weeks, median (IQR) 12 (6–26) 10 (4–20) 12 (8–26) <0.001
Missing, n (%) 168 (20) 43 (23) 123 (19)
Exposures, n (%) 158 (19) 29 (15) 129 (20) 0.18
Missing, n (%) 5 (0.6) 0 5 (1)
Smoking, n (%)
Never smoked 368 (44) 77 (41) 291 (45)
Former smoker 221 (26) 60 (32) 161 (25)
Smoker 208 (25) 39 (21) 169 (26)
Missing, n (%) 41 (5) 12 (6) 29 (4) 0.11
Marital status, n (%)
Married/co-inhabitant 565 (67) 120 (64) 445 (68)
Separated/divorced 97 (12) 30 (16) 67 (10)
Widow/widower 92 (11) 28 (15) 64 (10)
Unmarried/single 80 (9) 9 (5) 71 (11)
Missing, n (%) 4 (0.5) 1 (0.5) 3 (0.5) 0.005
Education, n (%)
Compulsory <12 years 178 (21) 31 (16) 147 (23)
Short <15 years/skilled worker 285 (34) 67 (36) 218 (34)
Medium academic/trade 234 (28) 57 (30) 177 (27)
Long academic/university level 131 (16) 32 (17) 99 (15)
Missing, n (%) 10 (1) 1 (0.5) 9 (1) 0.37
Occupation, n (%)
Employed 289 (35) 46 (25) 243 (37)
Retired/disability pay 516 (62) 139 (74) 377 (58)
Unemployed 29 (3) 3 (1) 26 (4)
Missing, n (%) 4 (0.5) 0 4 (9.6) 0.001
Cancer in family, n (%) 162 (19) 36 (19) 126 (19)
Missing, n (%) 20 (2) 4 (2) 16 (2) 0.96
Previous cancer in patient, n (%) 72 (9) 0 72 (11)
Missing, n (%) 7 (1) 0 7 (1) <0.001
Categorical variables are described as counts (%), and continuous variables are described as the mean (SD) or medians with the 25 to 75th interquartile ranges
(IRQ). Differences between patients diagnosed with cancer and patients not diagnosed were estimated using the Pearson χ2-test or Wilcoxon rank sum test,
as appropriate
Significant results are highligthed in bold
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The strongest predictors of clinical depression after a
known diagnosis were depression at baseline, degree of
SOC at baseline, (very) poor current SRH at baseline and
having two or more co-morbidities.
Discussion
Main findings
In this prospective study, a broad spectrum of PROs from
patients undergoing diagnostic evaluations for cancer be-
cause of non-specific symptoms was assessed in relation to
changes over time and the final diagnosis. Patients sus-
pected of cancer have similar HRQoL scores at the begin-
ning of diagnostic evaluations irrespective of their final
diagnosis. Goossens-Laan [40] found similar results in their
study on pre-diagnostic HRQoL in patients suspected of
having bladder cancer. Patients with a non-cancer diagnosis
improved in global QL, role and emotional functioning,
and they experienced fewer symptoms after a known diag-
nosis. Limited improvement over time was seen in patients
diagnosed with cancer. The patients diagnosed with cancer
were most likely early in their cancer trajectory at the time
of follow-up and therefore were still affected by the novelty
and insecurity of the situation.
Cognitive functioning was significantly higher at
baseline and deteriorated significantly more over time
in patients diagnosed with cancer. Cognitive function is
characterized by items asking how current illness might
affect concentration and memory. Although the baseline
score among cancer patients was higher than the other
functional domains, it is similar or lower than scores from
both normative and cancer reference groups [41]. More-
over, patients diagnosed with cancer had significantly
higher SOC scores than patients with a non-cancer diag-
nosis and a high SOC might serve as a determinant for
successful adaption to stressful situations [19].
Patients diagnosed with cancer also experienced more
dyspnea and appetite loss after a known diagnosis compared
with the non-cancer patients. Initiation of cancer treatment
could have an impact on these symptoms. However, al-
though we did not have information on initiation of treat-
ment, it is likely that few, if any, cancer patients had started
treatment at the time of follow-up assessment, because of
the short time period between referral and follow-up.
The most important impairment areas over time for
patients diagnosed with cancer compared to patients
with a non-cancer diagnosis were emotional, cognitive





















EORCT n=125 n=125 p-value n=549 n=549 p-value p-value ESc p-value ESc p-value ESc
Global Health/QL, mean (SD) 53 (23) 56 (27) 0.19 53 (24) 60 (25) <0.001 0.95 0.01 0.24 0.13 0.08 0.16
Functional scales, mean (SD)
Physical functioning 74 (24) 70 (27) 0.42 75 (23) 76 (23) 0.39 0.78 0.06 0.07 0.25 0.28 0.28
Role functioning 57 (35) 56 (36) 0.64 63 (34) 68 (32) <0.001 0.10 0.17 <0.001 0.38 0.06 0.22
Emotional functioning 74 (21) 73 (22) 0.39 70 (24) 75 (24) <0.001 0.07 0.19 0.13 0.08 <0.001 0.35
Cognitive functioning 84 (21) 80 (23) <0.01 79 (24) 79 (22) 0.35 <0.01 0.25 0.59 0.03 0.001 0.33
Social functioning 82 (26) 77 (30) 0.06 79 (26) 79 (28) 0.44 0.11 0.11 0.62 0.08 0.03 0.22
Symptom scales/items, mean (SD)
Fatigue 45 (31) 44 (30) 0.86 46 (28) 40 (27) <0.001 0.47 0.07 0.24 0.13 0.003 0.26
Nausea and vomiting 10 (17) 11 (19) 0.93 10 (17) 8 (16) <0.001 0.75 0.01 0.08 0.18 0.08 0.20
Pain 31 (31) 30 (31) 0.33 35 (32) 32 (31) <0.01 0.24 0.12 0.37 0.08 0.98 0.04
Dyspnea 27 (33) 25 (30) 0.52 22 (30) 19 (27) <0.01 0.12 0.17 0.02 0.24 0.63 0.04
Insomnia 31 (34) 33 (33) 0.53 34 (35) 32 (33) 0.31 0.39 0.09 0.88 0.01 0.30 0.12
Appetite loss 33 (38) 32 (36) 0.92 29 (35) 23 (32) <0.001 0.40 0.10 0.02 0.25 0.07 0.18
Constipation 15 (28) 19 (30) 0.47 15 (26) 14 (25) 0.32 0.59 0.01 0.12 0.18 0.26 0.19
Diarrhea 16 (27) 14 (26) 0.57 17 (28) 14 (24) <0.001 0.65 0.04 0.64 0.01 0.36 0.06
Financial difficulties 5 (15) 9 (18) <0.01 9 (24) 11 (25) 0.04 0.07 0.20 0.94 0.09 0.13 0.12
Bold values show statistical differences within and between groups
aWilcoxon signed-rank test
bWilcoxon rank sum test
cEffect size (ES) estimated by Cohen’s d; <0.20 = none, 0.20–0.49 = small, 0.50–0.79 =moderate, ≥0.80 = large
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and social functioning, and fatigue. These areas have
previously been identified as areas of concern in studies
with specific cancer patients prior to and after receiving
knowledge of their diagnosis [6, 7, 18, 42]. Affected role
functioning appears to be transient, whereas emotional
functioning and fatigue might continue for a long period
after the initial diagnosis and treatment [42].
Nearly one-third of patients experienced clinical anxiety
at baseline irrespective of the final diagnosis. Several studies
have reported a prevalence of anxiety ranging between
46 % and 73 % in the diagnostic phase of breast or lung
cancer [12, 43–46]. These studies included patients sus-
pected of having a specific type of cancer due to radio-
logical or symptomatic findings, thereby making the
possible threat of illness more specific. Patients referred to
the NSSC-CPP are not suspected of a specific cancer at re-
ferral. The most common symptoms at referral were non-
specific in nature, which could explain the lower levels of
anxiety in our study. Similar to our results, previous re-
search has suggested that patients who receive a non-
cancer diagnosis experience a larger decrease in anxiety
levels after known diagnosis than patients diagnosed with
cancer [2, 9, 10, 43, 45, 46]. However, it is important to
highlight that 28 % of patients in the non-cancer group
were experiencing clinical anxiety at follow-up. Receiving a
non-cancer diagnosis can have negative psychological ef-
fects and possibly delayed cancer diagnosis in case of subse-
quent cancer symptoms [1, 47, 48]. Thus, it is essential to
acknowledge the possible unintended consequences of a
non-cancer result, and provide sufficient information and
support to patients receiving a non-cancer diagnosis [48].
The strongest predictors of global QL after diagnosis
were the baseline global QL and depression scores,
(very) poor current SRH at baseline, age, co-morbidity
and unemployment. Age, co-morbidity and unemploy-
ment have been associated with poorer quality of life in
population studies [49–51]. Baseline HRQoL has been
shown to be predictive of health outcomes, such as the
survival rate and response to treatment, in cancer pa-
tients over time [52]. The global QL domain and SRH
Table 4 HADS, SOC and SRH scores at baseline and follow-up stratified by cancer diagnosis (yes/no), and the difference in change
between diagnosis groups
Cancer Not cancer


















HADS Anxiety, n (%) n=147 n=147 p-value n=519 n=519 p-value p-value ESd p-value ESd p-value ESd
Score <8 100 (68) 107 (73) 338 (65) 373 (72)
Score ≥8 47 (32) 39 (27) 181 (35) 146 (28)
Mean (SD) 0–21 5.6 (4.4) 5.4 (4.3) 0.58 6.3 (4.5) 5.4 (4.2) <0.001 0.09 0.16 0.84 0.02 0.01 0.20
HADS Depression, n (%) n=146 n=146 n=517 n=517
Score <8 113 (77) 113 (77) 386 (75) 397 (77)
Score ≥8 33 (23) 33 (23) 131 (25) 120 (23)
Mean (SD) 0–21 4.4 (4.1) 4.5 (4.3) 1.00 5.0 (4.1) 4.5 (4.2) 0.25 0.45 0.07 0.90 0.01 0.07 0.20
Sense of Coherence n=133 n=133 n=471 n=471
SOC Total score, median (IQR) 13–91 76 (68–83) 75 (67–81) 0.07 73 (61–80) 73 (62–80) 0.07 0.001 0.04 0.42
Self-rated Health
Self-rated Health currently, n (%) n=145 n=145 n=523 n=523
(very) good 36 (25) 36 (25) 0.13 96 (18) 104 (20) 0.68 0.06 0.12
fair 47 (32) 51 (35) 203 (39) 216 (41) 0.08 0.21
(very) poor 62 (43) 58 (40) 1.00 224 (43) 203 (39) 0.23 0.49 0.85 0.22
Self-rated Health compared
to 3 months, n (%)
n=145 n = 145 n=522 n=522
(very) good 10 (7) 24 (17) 0.12 44 (8) 149 (29) <0.001 0.73 <0.01
fair 54 (37) 60 (41) 248 (48) 264 (50) 0.03 0.06
(very) poor 81 (57) 61 (42) 0.02 230 (44) 109 (21) <0.001 0.01 <0.001 <0.01
Bold values show statistical differences within and between groups
aMcNemar’s χ2 for categorial data and Wilcoxon signed-rank test for continues data. For SRH the fair category was used as reference
bχ2 test for categorial data and Wilcoxon rank sum test for continues data
cWilcoxon rank sum test of the mean intragroup difference
dEffect size (ES) estimated by Cohen’s d; <0.20 = none, 0.20–0.49 = small, 0.50–0.79 =moderate, ≥0.80 = large
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items are similar in wording, which could explain the
strong association seen in the analysis [34–36]. Baseline
anxiety and depression have been significantly associated
with global QL impairment regardless of patients’ demo-
graphic and clinical characteristics [12]. Moreover, baseline
anxiety and depression scores were also associated with
clinical anxiety and depression after diagnosis. Our results
therefore highlight the importance of including pre-
diagnostic baseline assessments when looking at the psy-
chological impact of a cancer diagnosis [53].
The degree of SOC was a significant predictor of clinical
anxiety and depression after diagnosis; a finding supported
by several studies [32, 54]. A high SOC has been associated
with better perceived health and quality of life within differ-
ent samples, including cancer patients [32, 55, 56]. SOC did
not change over time, thereby supporting the original per-
ception of SOC as a staple dispositional orientation with
limited fluctuations in stressful situations [19].
Receiving a cancer diagnosis did not have an effect on
global QL, anxiety or depression scores after known
diagnosis. The risk of anxiety increased by nearly 50 % in
patients who completed the follow-up prior to receiving
knowledge of their diagnosis, highlighting the impact of
the diagnostic phase irrespective of final diagnosis.
Knowledge of diagnosis might be protective of clinical
anxiety, and several studies have shown that the timeliness
of diagnosis might have a beneficial effect on anxiety and
depression irrespective of the final diagnosis [4, 9, 43].
Strengths and limitations of the study
A major strength of this study is the prospective, multicen-
ter design with a large number of consecutive patients. Diag-
nosis and co-morbidity data were collected via the National
Patient Registry, which is considered to be precise and valid
[37]. Patients were encouraged to complete the baseline
questionnaire prior to receiving knowledge of their diagno-
sis. However, as patients were experiencing symptoms and
were informed about the suspicion of cancer at baseline, this
questionnaire might not render a true baseline measure-
ment. Overall, the effect sizes were low and clinical differ-
ences in scores were found in the role functioning domain
only. Thus, the clinical impact of the observed difference
within and between the diagnosis groups may be limited.
However, this could be because the follow-up was collected
too close to the diagnostic phase to assess the impact of
diagnosis in patients suspected of cancer. The focus of this
study was to assess patient experience from referral to diag-
nosis, as this has not previously been described in this pa-
tient population. Although of interest, a long-term follow-up
goes beyond the scope of the study.
The overall response rate was low; only 39 % of eligible
patients participated. However, a low response rate does not
necessarily indicate non-response bias [57, 58] because the
differences between enrolled patients and non-participating
patients were small. ‘Consent only’ patients were younger
and less likely to have cancer, and a possible explanation for
their decision not to enroll might be that they were eager to
return to normal life. Enrolled patients were more often re-
ferred to the NSSC-CPP due to suspicion of having cancer
or other reasons, indicating that the data collection methods
were not precise enough. A recent study found that patients
referred to the NSSC-CPP consist of a very heterogeneous
group presenting with over 80 different symptoms [59].
Similar to other studies, we found weight loss, pain and fa-
tigue to be the most common symptoms at referral [59].
We found an overall probability of cancer of 22 % in our
sample, which is higher than in other studies
[59, 60], but similar to the national surveillance data [17].
Because only four and 11 patients had a prior history of anx-
iety or depression, respectively, a prior history of anxiety
and/or depression was not included in the multivariate ana-
lysis due to the small numbers.
Conclusion
Patients suspected of having a cancer illness experience
a high prevalence of anxiety and had an affected quality
of life prior to receiving knowledge of their diagnosis.
Patients who were not diagnosed with cancer experience
Table 5 Adjusted bootstrapet multiple linear regression analysis
of the determinants of global quality of life at follow-up
Global QL
Coeff 95 % CI p-value
Intercept 29.90 (10.71; 49.09) 0.002
Baseline global QL 0.38 (0.28; 0.48) <0.001
HADS Anxiety at baseline 0.08 (−0.42, 0.58) 0.75
HADS Depression at baseline −1.19 (−1.81; −0.59) <0.001
SOC at baseline 0.13 (−0.04; 0.30) 0.13
Self-rated health, currently at baseline
(very) good Reference
fair −3.13 (−7.28; 1.03) 0.14
(very) poor −9.28 (−14.25; −4.32) <0.001
Age 0.21 (0.04; 0.38) 0.02
Co-morbidity
0 Reference
1 −5.14 (−8.63; −1.66) 0.004
≥2 −6.28 (−10.56; −2.01) 0.004
Occupation
Employed Reference
Unemployed −8.32 (−16.16; −0.49) 0.04
Retired/disability/early retirement −3.97 (−8.14; 0.19) 0.06
Non-significant predictors including gender, time of follow-up completion, SRH
compared to 3 months ago at baseline, cancer diagnosis (yes/no), marital status,
education, previous cancer in patient and hospital were excluded from the
table. R2 = 0.48
Significant results are highligthed in bold
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a large improvement compared to patients diagnosed
with cancer. The predictive value of the baseline PRO
scores are important when assessing the psychological
impact of undergoing diagnostic evaluations for cancer.
Further research is needed to explore any long-term
psychological implications of going through diagnostic
evaluations for possible cancer.
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